Scientists from the University of Oxford, Newcastle University, and Cambridge University Hospitals NHS Foundation Trust have uncovered a previously unexplained cause of inflammatory bowel disease (IBD). The discovery could change how doctors understand, diagnose, and treat certain forms of the condition. The findings indicate that IBD is not simply one disease.
Instead, it appears to include several biologically distinct conditions that develop through different processes in the body. Identifying these differences could make it possible to provide treatments tailored to the specific cause of each patient's illness. In a study published in the New England Journal of Medicine, researchers examined more than 4,900 people with IBD and identified two important findings.
First, some patients produce antibodies that interfere with interleukin-10 (IL-10), an essential protein that helps prevent excessive inflammation. Second, this autoimmune reaction explains how one of the strongest known genetic risk factors for IBD contributes to the disease. Under normal circumstances, IL-10 acts as a chemical messenger between cells, helping the immune system regulate inflammation.
However, certain antibodies can block its activity, effectively disabling one of the body's built-in safeguards against excessive immune responses. Without this protection, inflammation can persist and become difficult to control. Hidden Antibodies Reveal a Cause of Inflammatory Bowel Disease Inflammatory bowel disease includes Crohn's disease and ulcerative colitis, two chronic conditions that affect approximately 500,000 people in the UK and millions more around the world.
Symptoms often first appear during adolescence or early adulthood, and patients may face lifelong medical challenges. Managing the disease can involve repeated hospital visits, medications that suppress immune activity, and sometimes surgery. Although treatments have improved, many people must try several different therapies without achieving lasting relief.
This places a substantial burden on patients and creates significant costs for healthcare systems. The researchers discovered that approximately 3.5% of patients with IBD had elevated levels of antibodies that neutralize IL-10. These antibodies were detected in people with both Crohn's disease and ulcerative colitis, but not in healthy individuals.
Extract — continue reading at the source.
